These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20842829)

  • 1. [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):131-4. PubMed ID: 20842829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rituximab in systemic lupus erythematosus. Part II: review of clinical experience].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):135-40. PubMed ID: 20842830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Kazkaz H; Isenberg D
    Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
    Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
    Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
    Dörner T; Kinnman N; Tak PP
    Pharmacol Ther; 2010 Mar; 125(3):464-75. PubMed ID: 20097226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus.
    Lee SY; Hsu PY; Juan KC; Chang H; Huang WH; Lai PC
    Int Immunopharmacol; 2010 May; 10(5):632-4. PubMed ID: 20172055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
    Smith MR
    Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug insight: rituximab in renal disease and transplantation.
    Salama AD; Pusey CD
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.